GlaxoSmithKline (GSK)

GSK Calls It Quits on Two Cancer Trials for Feladilimab

April 16, 2021

GlaxoSmithKline (GSK) has halted enrollment in two phase 2 trials evaluating feladilimab as a treatment for patients with head and neck cancer.

GSK said it made the decision to end its INDUCE-3 study following a recommendation from the trial’s independent data monitoring committee. The trial has been assessing feladilimab, an antibody that stimulates T-cells, in combination with Merck’s Keytruda (pembrolizumab) for treating patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma.

GSK has also ended the follow-up INDUCE-4 trial evaluating the drug with Keytruda and chemotherapy vs. placebo. The UK drugmaker said it will “assess the impact on the overall clinical development program for feladilimab.”

View today's stories